MK-677 (Ibutamoren) Dosage Guide

MK-677 stands apart from every other growth hormone peptide: you swallow it. Ibutamoren is an oral, non-peptide growth hormone secretagogue that stimulates the ghrelin receptor to produce sustained GH and IGF-1 elevation with a single daily dose. No reconstitution, no syringes, no injection sites.

That convenience comes with trade-offs: significant appetite stimulation, water retention, and a real concern about blood sugar and insulin sensitivity. MK-677 (Ibutamoren mesylate) was developed by Merck as a small molecule that mimics ghrelin. Unlike Ipamorelin or GHRP-6, MK-677 is not a peptide — it's a synthetic compound with oral bioavailability and a long half-life that allows once-daily dosing.

Use our Peptide Dosage when stacking MK-677 with injectable peptides.

For a complete overview of its mechanism and research, see our full MK-677 profile. New to peptides? Start with the Beginner's Guide to Peptides.

MK-677 is dosed in milligrams (mg) once daily. Unlike injectable peptides measured in micrograms, MK-677 uses straightforward oral dosing. The table below summarizes the three commonly used dosing tiers.

MK-677's sustained GH and IGF-1 elevation makes it applicable across multiple goals. The optimal dose, timing, and cycle length vary by what you are trying to achieve.

Anti-Aging & GH Optimization

The Nass et al. (2008) study demonstrated that MK-677 restored GH and IGF-1 levels in older adults to those seen in younger populations. Lower doses are preferred for this application to minimize metabolic side effects during extended use.

• Dose: 10–15 mg/day
• Timing: Bedtime
• Cycle: 3–6 months on, 1–2 months off (or 5 days on, 2 days off weekly)
• Key concern: Monitor fasting glucose closely with extended use

Muscle Growth & Recovery

Murphy et al. (1998) showed +3 kg fat-free mass over 8 weeks at 25 mg/day. Higher doses are used here to maximize GH and IGF-1 elevation, which supports muscle protein synthesis, recovery, and lean mass accrual when combined with resistance training.

• Dose: 20–25 mg/day
• Timing: Bedtime
• Cycle: 8–12 weeks on, 4 weeks off
• Key concern: Appetite management; strict dietary discipline required to avoid fat gain

Sleep Quality

Copinschi et al. (1997) demonstrated that a single 25 mg dose increased GH secretion during sleep by 50–70%. Many users report subjectively improved sleep quality, deeper sleep, and vivid dreams. Lower doses are sufficient for this application.

• Dose: 10–15 mg/day
• Timing: Before bed (30–60 minutes)
• Cycle: Can be used longer-term at lower doses with monitoring
• Key concern: Some users report excessive grogginess at higher doses

Bone Density Support

GH and IGF-1 are critical regulators of bone metabolism. The 2-year Nass et al. study provided data on bone mineral density changes. Higher doses and longer durations are used for this application, under medical supervision.

• Dose: 25 mg/day
• Timing: Bedtime
• Cycle: 6–12 months (under physician supervision)
• Key concern: Extended use requires regular blood sugar and metabolic monitoring

Fat Loss (Indirect)

MK-677 does not directly burn fat. Any fat loss benefit is indirect — through increased GH and IGF-1 supporting lean mass retention, improved recovery from training, and increased energy expenditure (Svensson et al., 1998). The strong appetite stimulation makes MK-677 counterproductive for fat loss unless dietary discipline is strict.

• Dose: 15–20 mg/day
• Timing: Bedtime (to minimize daytime appetite)
• Cycle: 8–12 weeks
• Key concern: Strict dietary control is essential; appetite management is the primary challenge

Blood sugar monitoring is not optional with MK-677. The Nass et al. (2008) study confirmed that 25 mg/day increased fasting glucose in older adults over 2 years. Growth hormone is inherently diabetogenic — it promotes insulin resistance by shifting fuel utilization toward fat and away from glucose. MK-677's sustained GH elevation amplifies this effect.

Monitoring Protocol

MK-677 has a well-characterized side effect profile from clinical trials lasting up to 2 years. Side effects are generally dose-dependent and predictable. The primary clinical concern is the impact on glucose metabolism and insulin sensitivity.

Very Common Side Effects

Expected in most users, especially during the first 2–4 weeks:

• Increased appetite — ghrelin receptor activation; strongest side effect
• Water retention and bloating — GH-mediated sodium retention; stabilizes after 2–3 weeks
• Lethargy and grogginess — more common at higher doses; may affect morning alertness

Common Side Effects

• Numbness and tingling in extremities — related to GH elevation; typically mild
• Muscle aches and joint stiffness — GH-related, more common at 25 mg
• Vivid dreams — frequently reported; generally not unpleasant
• Mild fasting glucose increase — dose-dependent; requires monitoring

Clinically Significant

• Elevated fasting glucose and insulin resistance — the primary metabolic concern. GH is inherently diabetogenic. Confirmed in the 2-year Nass et al. study. Requires baseline and ongoing blood sugar monitoring.
• Elevated blood pressure — water and sodium retention can increase blood pressure, particularly in predisposed individuals. Monitor if you have hypertension or are on BP medications.

Contraindications

• Diabetes or pre-diabetes — MK-677 worsens insulin sensitivity and raises fasting glucose. Use is strongly discouraged in individuals with existing glucose dysregulation.
• Active cancer — GH and IGF-1 promote cell growth. Elevated IGF-1 levels are associated with increased cancer risk in epidemiological studies. Avoid use with active malignancies or a history of GH-sensitive cancers.
• Pregnancy and breastfeeding — no safety data exists. Avoid use entirely.
• Congestive heart failure (CHF) — water and sodium retention can worsen fluid overload in heart failure patients.
• Children and adolescents — MK-677 has not been studied in pediatric populations. The effects on growing bodies are unknown.

Drug Interactions

• Insulin and diabetes medications: MK-677 raises blood glucose, potentially requiring dose adjustments of diabetes medications. Do not combine without physician oversight.
• Blood pressure medications: Water retention from MK-677 may counteract antihypertensive therapy. Monitor blood pressure closely.
• Other GH secretagogues: Stacking MK-677 with Ipamorelin, CJC-1295, GHRP-6, or other GH-releasing peptides produces additive GH elevation and increases the risk of GH-related side effects.
• Corticosteroids: Both MK-677 and corticosteroids can raise blood glucose. Concurrent use increases the risk of hyperglycemia.

When to Stop

• Fasting glucose exceeds 100 mg/dL or rises more than 10 mg/dL from baseline
• Persistent swelling, edema, or fluid overload that does not resolve
• Chest pain, shortness of breath, or cardiovascular symptoms
• Persistent numbness, tingling, or carpal tunnel symptoms
• Signs of fluid overload — sudden weight gain, ankle swelling, difficulty breathing